BACKGROUND: The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making. OBJECTIVE: To investigate the prognostic value of circulating tumor cell (CTC) enumeration and dynamics, in the context of second-line endocrine therapies (ie, abiraterone acetate or enzalutamide), irrespective of prior systemic therapies. DESIGN, SETTINGS, AND PARTICIPANTS: In a prospective, multicentre study blood samples for CTC enumeration were collected from patients with mCRPC at baseline (n = 174). In patients who responded for minimally 10-12 weeks a follow-up sample was collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For baseline analysis, patients were stratified in <5 or ≥5 CTCs/7.5 mL, whereas for the analysis of CTC dynamics at 10-12 weeks, in patients with stable, increasing or decreasing CTC counts. Progression-free survival (PFS), overall survival (OS), and PSA changes at 10-12 weeks were compared between groups. RESULTS: Patients demonstrating increasing CTCs on therapy had a shorter median PFS (4.03 vs 12.98 vs 13.67 months, HR 3.6, 95%CI 1.9-6.8; P < 0.0001) and OS (11.2 months vs not reached, HR 9.5, 95%CI 3.7-24; P < 0.0001), compared to patients with decreasing or stable CTCs. Multivariable Cox regression showed that prior chemotherapy (HR 4.1, 95%CI 1.9-8.9; P = 0.0003), a high baseline CTC count (HR 1.5, 95%CI 1.2-1.9; P = 0.002) and increasing CTCs at follow-up (HR 3.3, 95%CI 1.4-7.6; P = 0.005) were independent predictors of worse PFS. Previous chemotherapy (HR 7, 95%CI 1.9-25; P = 0.003), high baseline CTC counts (HR 2.2, 95%CI 1.4-3.7; P = 0.002) and increasing CTCs during therapy (HR 4.6, 95%CI 1.4-15; P = 0.01) were independently associated with shorter OS. ≥30% and ≥50% PSA responses less frequently occurred in patients with CTC inclines at 10-12 weeks on therapy (χ2 test: P < 0.01). CONCLUSIONS: CTC dynamics during therapy are associated with PSA response and provide independent clinical prognostication over PSA declines. Hence the study demonstrates the pharmacodynamic properties of CTCs.
BACKGROUND: The outcome to treatment administered to patients with metastatic castration-resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making. OBJECTIVE: To investigate the prognostic value of circulating tumor cell (CTC) enumeration and dynamics, in the context of second-line endocrine therapies (ie, abiraterone acetate or enzalutamide), irrespective of prior systemic therapies. DESIGN, SETTINGS, AND PARTICIPANTS: In a prospective, multicentre study blood samples for CTC enumeration were collected from patients with mCRPC at baseline (n = 174). In patients who responded for minimally 10-12 weeks a follow-up sample was collected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For baseline analysis, patients were stratified in <5 or ≥5 CTCs/7.5 mL, whereas for the analysis of CTC dynamics at 10-12 weeks, in patients with stable, increasing or decreasing CTC counts. Progression-free survival (PFS), overall survival (OS), and PSA changes at 10-12 weeks were compared between groups. RESULTS:Patients demonstrating increasing CTCs on therapy had a shorter median PFS (4.03 vs 12.98 vs 13.67 months, HR 3.6, 95%CI 1.9-6.8; P < 0.0001) and OS (11.2 months vs not reached, HR 9.5, 95%CI 3.7-24; P < 0.0001), compared to patients with decreasing or stable CTCs. Multivariable Cox regression showed that prior chemotherapy (HR 4.1, 95%CI 1.9-8.9; P = 0.0003), a high baseline CTC count (HR 1.5, 95%CI 1.2-1.9; P = 0.002) and increasing CTCs at follow-up (HR 3.3, 95%CI 1.4-7.6; P = 0.005) were independent predictors of worse PFS. Previous chemotherapy (HR 7, 95%CI 1.9-25; P = 0.003), high baseline CTC counts (HR 2.2, 95%CI 1.4-3.7; P = 0.002) and increasing CTCs during therapy (HR 4.6, 95%CI 1.4-15; P = 0.01) were independently associated with shorter OS. ≥30% and ≥50% PSA responses less frequently occurred in patients with CTC inclines at 10-12 weeks on therapy (χ2 test: P < 0.01). CONCLUSIONS: CTC dynamics during therapy are associated with PSA response and provide independent clinical prognostication over PSA declines. Hence the study demonstrates the pharmacodynamic properties of CTCs.
Authors: Irene Casanova-Salas; Alejandro Athie; Paul C Boutros; Marzia Del Re; David T Miyamoto; Kenneth J Pienta; Edwin M Posadas; Adam G Sowalsky; Arnulf Stenzl; Alexander W Wyatt; Joaquin Mateo Journal: Eur Urol Date: 2021-01-07 Impact factor: 24.267
Authors: Katrin Schlack; Laura-Maria Krabbe; Kambiz Rahbar; Karoline Isenberg; Axel Semjonow; Andres Jan Schrader; Martin Boegemann Journal: Transl Androl Urol Date: 2021-10
Authors: G Francolini; M Loi; V Salvestrini; M Mangoni; B Detti; V Di Cataldo; M Aquilano; P Pinzani; F Salvianti; I Desideri; M Mariotti; P Garlatti; G Stocchi; L P Ciccone; S Lucidi; G Salvatore; M Sottili; I Meattini; L Livi Journal: Clin Exp Metastasis Date: 2021-08-19 Impact factor: 5.150
Authors: Renata Poteska; Kambiz Rahbar; Axel Semjonow; Andres Jan Schrader; Martin Boegemann; Katrin Schlack Journal: BMC Cancer Date: 2022-04-08 Impact factor: 4.430
Authors: Markus Mayrhofer; Bram De Laere; Tom Whitington; Peter Van Oyen; Christophe Ghysel; Jozef Ampe; Piet Ost; Wim Demey; Lucien Hoekx; Dirk Schrijvers; Barbara Brouwers; Willem Lybaert; Els Everaert; Daan De Maeseneer; Michiel Strijbos; Alain Bols; Karen Fransis; Steffi Oeyen; Pieter-Jan van Dam; Gert Van den Eynden; Annemie Rutten; Markus Aly; Tobias Nordström; Steven Van Laere; Mattias Rantalainen; Prabhakar Rajan; Lars Egevad; Anders Ullén; Jeffrey Yachnin; Luc Dirix; Henrik Grönberg; Johan Lindberg Journal: Genome Med Date: 2018-11-21 Impact factor: 11.117
Authors: Juho Jasu; Teemu Tolonen; Emmanuel S Antonarakis; Himisha Beltran; Susan Halabi; Mario A Eisenberger; Michael A Carducci; Yohann Loriot; Kim Van der Eecken; Martijn Lolkema; Charles J Ryan; Sinja Taavitsainen; Silke Gillessen; Gunilla Högnäs; Timo Talvitie; Robert J Taylor; Antti Koskenalho; Piet Ost; Teemu J Murtola; Irina Rinta-Kiikka; Teuvo Tammela; Anssi Auvinen; Paula Kujala; Thomas J Smith; Pirkko-Liisa Kellokumpu-Lehtinen; William B Isaacs; Matti Nykter; Juha Kesseli; G Steven Bova Journal: Eur Urol Open Sci Date: 2021-07-02